Prev Close | 9.25 |
Day Low/High | 0.00 / 0.00 |
52 Wk Low/High | 3.46 / 9.28 |
Prev Close | 9.25 |
Day Low/High | 0.00 / 0.00 |
52 Wk Low/High | 3.46 / 9.28 |
Exchange | NASDAQ |
Div & Yield | N.A. (N.A) |
The names include a veterinary drug concern plus companies with successful drugs on the market.
Aratana Therapeutics and Kindred Biosciences are promising drug developers in the pet space.
We've made a few tweaks due to price changes, while others were based on a last-minute assessment of better value.
The second half of our value-stocks portfolio for the New Year.
Kindred Biosciences and GM may be 'too cheap not to own.'
Even if the markets were to take a dive, the strength of our holdings will prevail.
These 3 names may not draw attention, but they can draw profits.
A group of seven to 15 securities, if carefully selected, can provide all the diversification an investor needs.
Brexit has caused active investors to flee and created an opportunity for those who are patient.
The energy rally is a good example.
Sometimes, the under-research companies offer the biggest opportunities.
Investors should see this selection as one part of a multi-year investment program.
Investors dump losing positions to start 'fresh' in 2016.
My Winning Value Portfolio didn't live up to its name in 2015.
August was a month to forget, dragged down by the energy names.
Despite portfolio performance, valuations of most of the stocks appear to be as compelling as ever.
Only Chenier Energy was a winner among these 10 names.
'Doing nothing' delivered in April.
A weak March showing isn't catastrophic, but be ready for more pain.
Despite underperforming so far, the portfolio is well undervalued.
Off to a slow start, but time is still on our side in 2015.
All that matters is valuation and potential upside.
A probabilistic biotech play.
Many value investors are making more concentrated bets.
Bill Ackman is betting on Zoetis -- and you should, too.
The stock's recent decline makes upside even more appealing.
The 15% jump yesterday means little in my scheme of things.
Amid the basket's impressive performance, I'm adding Minerva.
When the Fed knocks down certain market sectors, we value investors know what to do.
Borrowing a page from a master investor's playbook.